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harmaceutical regulatory change is driven by 
a number of factors, one of the most influential being 
the harmonization process lead by the International
Conference on Harmonization of Technical Requirements
for Registration of Pharmaceuticals for Human Use
(ICH).(Detailed information and guidelines are avail-
able on the ICH homepage.
1) The ICH is essentially com-
posed of six parties:the three major regulatory authori-
ties of the USA, Europe, and Japan, and the three
corresponding associations of pharmaceutical manufac-
turers. It would seem natural that the guidelines pro-
duced by the ICH are international in scope and purpose.
The ICH produces “soft law”regulations that are by def-
inition not legally binding.An ICH guideline has no more
binding power than a resolution of the General Assembly
of the United Nations.Once adopted by a country,they
may become as binding as law (for example, the new
Japanese good clinical practice [GCP] guidelines). As
with resolutions,guidelines are adopted in a consensual
way and reflect the minimum status of agreement on any
topic. Considering this, the ICH has been successful in
harmonizing regulations from all regions into one set of
rules acceptable to all.Japan has accepted the changes
necessary to reach agreement.
The regulatory authority
The Japanese regulatory authority is not well known to the
rest of the world,as is the Food and Drug Administration
(FDA).Japanese information is hard to access because of
differences in language and culture. It is true that the
Japanese Ministry of Health,Labor,and Welfare (MHLW)
is a complex organization,although any regulatory author-
ity is by definition complex.Its ancestor,the Ministry of
Health and Welfare (MHW),implemented many current
regulations and decisions.Information on both organiza-
tions is available on the Internet.
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Drastic regulatory changes in Japan since 1997 have had
a considerable impact on the way new medicines are
developed. The regulatory authority itself has been trans-
formed. Clinical trials are now performed according to
international guidelines. Clinical data generated in one
area are acceptable in the rest of the world in some cases
through a bridging process that is viewed as only tempo-
rary. The future of drug development lies in multinational
clinical trials and simultaneous submission to the major
regulatory authorities.
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The pharmaceutical regulatory authority of Japan is the
Pharmaceutical and Food Safety Bureau (PFSB) of the
MHLW.This is where the decision for application approval
is formally made.Two other bodies deal with the pharma-
ceutical industry on a day-to-day basis.The Pharmaceuti-
cals and Medical Devices Evaluation Center (PMDEC),
usually known as “The Center,” is the actual decision-
maker for approval of new drug applications (NDAs).The
Organization for Pharmaceutical Safety and Research
(OPSR), also known as “Kiko” or “the DO” (Drug
Organization), is an independent body, related to the
MHLW,that is in charge of discussing drug development
programs with industry.A merger of these two organiza-
tions has been announced in the past few years,and would
result in the creation of an equivalent to the American
FDA. The three aforementioned organizations are
involved in approval reviews,and the regulatory body and
ultimate decision-maker is the MHLW.Although it is not
a requirement,companies are strongly advised to negoti-
ate their development programs with the DO. More
detailed information can be found in Pharmaceutical
Administration and Regulations in Japan 2002,published
by Japanese Pharmaceutical Manufacturers Association
(JPMA) on their homepage.
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The structure of Japanese regulations regarding develop-
ment of pharmaceuticals is as follows:the Pharmaceutical
Affairs Law (PAL), and especially its Article 14, is the
organizing principle.This law is currently being revised.
The MHLW implements legally binding regulations by
way of ordinances.This is the way the MHLW has chosen
to publish the PAL enforcement guidelines and,in 1997,
to implement the guideline ICH E6,regarding GCP.
Lesser regulations can be easily implemented through
publication of a “Notification of the Pharmaceutical and
Medical Safety Bureau (PMSB),”which makes them not
legally binding.These regulations must be followed in
order to obtain regulatory approval. This is how the
guideline ICH E5 or the “ethnicity guideline”was intro-
duced in Japan.Many other guidelines exist and,like in
many other countries,older regulations sometimes coex-
ist with newer ones.Old guidelines may remain applica-
ble and it is important to consider following them,or else
providing the MHLW with a reasonable argument
regarding their obsolescence.
A revolution in Japan
The implementation in Japan in 1997 of the GCP guide-
line ICH E6,known in Japan as “the new GCP,”has had
a considerable and almost revolutionary effect on the
Japanese regulatory environment.Although ICH guide-
lines are usually simply translated into Japanese,ICH E6
was published in three separate documents, the most
important of which is the Ministry Ordinance #28.An
English translation of the Japanese GCP is available.
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Traditionally,the pharmaceutical industry does not receive
a lot of trust from the public in Japan,following a number
of scandals in past and recent years.Western medicines are
seen as potentially dangerous,and the Japanese authori-
ties have always put the emphasis on safety and quality
issues,rather than efficacy.Incentives for patients taking
part in clinical trials were already low,because of the com-
prehensive coverage of medical costs that Japan offers,and
the very strict rules for compensation. Doctors have no
financial incentive,and academic incentive is limited in a
pharmaceutical world in which Japan is usually the last
place where companies develop their drugs.When a drug
is first developed in the US and Europe,nothing of inter-
est is left for the Japanese investigators to publish.
The guideline worsened a situation that was already bad.
Many organizations involved in clinical research found in
1997 and 1998 that they were unable to cope with the new
regulations. The new written informed consent was a
major difficulty,having been designed for a culture where
doctors pay heavy malpractice insurance fees,and patients
can sue if something goes wrong.Although the degree of
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CRC clinical research coordinators
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Pharmaceuticals for Human Use
MHLW Ministry of Health,Labor,and Welfare
NDA new drug application
OPSR Organization for Pharmaceutical Safety and
Research
PAL Pharmaceutical Affairs Law
PFSB Pharmaceutical and Food Safety Bureau
PMDEC Pharmaceuticals and Medical Devices Evaluation
Center
SMO site management organizationtrust in their doctors has also decreased in Japan, it
remains very high,and doctors would usually only have to
“advise”their patients that a certain trial would be bene-
ficial to obtain oral consent.
Therefore, the practice of written consent became an
issue,given that doctors lacked the time and training to
obtain it, and that staff such as trial nurses or clinical
research coordinators (CRCs) were not available.
Contract research organizations (CROs) or site man-
agement organizations (SMOs) did not have the work-
force necessary to help the industry and hospitals adapt
to the new regulations.
In the years that followed, the number of patients
involved in clinical trials was cut by half,as was the num-
ber of trials,number of submissions,and number of reg-
ulatory approval for new drugs.It is only now,more than
5 years after the new GCP went into effect,that the num-
bers have started to increase.This is mainly the result of
a tremendous involvement in clinical research of CROs
and SMOs.
In 1997 the new GCP regulations allowed the CROs to
take over responsibility of phase 2 and 3 clinical trials.The
availability of skilled personnel has been the limiting fac-
tor for these companies and they struggle to recruit new
staff in the population of pharmacy graduates.As a result,
CROs in Japan are still extremely busy,and availability is
minimal.
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SMOs traditionally staffed phase 1 units,and had to be
legally separate from CROs for fear of collusion (indus-
try and hospitals must stay apart:CROs help industry;
SMOs help hospitals).In hospitals involved in phase 2
and 3 clinical trials, SMOs now assume the training of
physicians and nurses, setup of clinical trial centers,
staffing with the CRCs, writing of standard operating
procedures (SOPs), and interaction with monitors or
auditors from the regulatory authority.Even more than
CROs,SMOs suffer from a lack of qualified staff.Most
CRCs in Japan are currently involved in the training of
other CRCs.
The concept of ethnic bridging
The guideline ICH E5,the ethnicity guideline,
6 can also
be qualified as one of the most influential guidelines of
the past few years in Japan.The aim of this guideline was
to reduce duplication of clinical studies by setting up a
process for evaluating the possibility of extrapolating
clinical data from one regulatory area to another.
Overall,this guideline has been successful in reducing the
necessity to reproduce clinical research programs in
Japan for drugs that have already been approved in the
West.The guideline describes in detail which drugs may
be more easily “bridged” from one area to the other.
Experience has proven that it is by closely negotiating
with the DO that companies have the best chances of
obtaining approval.
In all cases,additional information regarding the phar-
macokinetics of the drug in the new population is
needed.This can be done by comparing data obtained in
Caucasian volunteers with new data obtained in Japanese
subjects in Japan or in the West.The best way is to design
a comparative trial involving both Japanese and Western
subjects in one protocol. The guideline is carefully
worded to allow these studies to be performed in Japan,
in the West,in one site,or in two sites.All possible com-
binations have been tried,and none is completely satis-
factory.
Single-site studies conducted in the West have been faced
with the difficulty of recruiting Japanese volunteers out-
side of Japan.The subjects’ visa situation as well as tax
issues have limited the availability. In addition, the
authorities regularly question the quality of the Japanese
subjects recruited abroad.
Two-site studies simplify the question of recruiting,each
arm of the study being conducted locally.The difficulty
here lies in harmonization of the protocol to fit two facil-
ities,and in cross-training of the staff to perform the same
study in two different locations.
The number of foreigners present in Japan limits single-
site studies conducted in Japan with Caucasian volun-
teers.We have succeeded in creating a panel of approx-
imately 450 volunteers, most of them located in the
Kanto area. This method is of the greatest interest to
Japanese authorities as well as pharmaceutical compa-
nies.Ultimately,ethnicity is a political concept,and there
is no absolute way to determine it scientifically. Here
again, the quality of foreign subjects in Japan may be
questioned, and several ways to assess ethnicity have
been designed,to the satisfaction of Japan’s regulatory
authority.The data generated this way have been judged
acceptable by the MHLW.
ICH E5 defines two types of ethnic factors that may have
an influence on drug development. Intrinsic factors are
genetic and related to the actual human population of the
regulatory area.Extrinsic factors are related to the culture
of the area.Early after the publication of the guideline in
Clinical research
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Japan, attention was focused on intrinsic ethnic factors,
especially genetic differences in drug metabolism.It is true
that the frequencies of various types of metabolizers for
mephenytoin or cytochromes is notably different accord-
ing to the country considered.However,this is no longer
considered a major problem in bridging strategies.
The future of drug development
The regulatory authorities of Japan have consistently
expressed the view that major bridging issues lie rather
on the side of extrinsic factors,such as differences in dis-
ease definitions,modalities of treatment,application of
GCP regulations,and the design of clinical trials,espe-
cially for the selection of end points.
It has also been clear that the bridging process is a tem-
porary one.It actually constituted a threat to Japanese
clinical and medical research,with fewer and fewer clin-
ical trials being conducted in Japan. With the help of
CROs and SMOs,this trend is already changing,and the
numbers of consultations with the DO are rapidly
increasing,for bridging strategies as well as traditional
and global drug development.For companies,it is easier
to market a new drug in a country where it has been
tested and where opinion leaders are familiar with it.The
incentives for physicians in clinical research are increased
by the possibility of publishing interesting data.
The future of drug development lies therefore in its glob-
alization.Large pharmaceutical corporations have started
to conduct multinational phase 3 trials involving Western
and Japanese sites, leading to global simultaneous sub-
mission to the main regulatory authorities of the World.
This will be facilitated by the adoption of a common tech-
nical document (CTD) framework for electronic submis-
sions.Global submission and approval will bring the prod-
ucts to the main pharmaceutical markets quicker,to the
benefit of the industry and patients.These strategies must
be taken into account as early as possible in the drug
development process.
The participation of international CROs is needed to
help pharmaceutical companies implement these strate-
gies.In the particular case of Japan,knowledge of inter-
national and national regulations is not enough.
Companies need to have a good understanding of cul-
tural differences to negotiate their drug development
programs with the authorities. ❏
Revisión del entorno farmacéutico y de la
reglamentación en Japón
Los drásticos cambios en las medidas regulatorias
en Japón desde 1997 han tenido un impacto consi-
derable en la forma cómo se han desarrollado nue-
vas medicinas. La misma autoridad regulatoria se
ha transformado. Los ensayos clínicos ahora se rea-
lizan de acuerdo con guías internacionales. Los
datos clínicos generados en un área son aceptados
en el resto del mundo en algunos casos a través de
un proceso de puente, lo que parece ser sólo tem-
poralmente. El futuro del desarrollo de fármacos
depende de los ensayos clínicos multinacionales y
de la presentación simultánea a las principales
autoridades regulatorias.
Environnement pharmaceutique et régle-
mentaire japonais
Les changements réglementaires draconiens au
Japon depuis 1997 ont eu un impact considérable
sur le développement des nouveaux médicaments.
L’autorité réglementaire elle-même a été transfor-
mée. Les essais cliniques sont maintenant réalisés
selon les directives internationales. Dans certains
cas, les données cliniques collectées dans une par-
tie du monde sont acceptables pour le reste du
monde par l’intermédiaire d’une procédure relais
considérée comme temporaire seulement. L’avenir
du développement du médicament repose sur des
essais cliniques multinationaux et la soumission
simultanée aux autorités réglementaires princi-
pales.Clinical research
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